IGF::OT::IGF SBIR PHASE I, TOPIC 331: OPTICAL SPECTROSCOPY CAPABLE BIOPSY NEEDLE TIP TO SEEK HIGH TUMOR CONTENT AREAS

Information

  • Research Project
  • 8945763
  • ApplicationId
    8945763
  • Core Project Number
    N43CO000000
  • Full Project Number
    261201400058C-0-0-1
  • Serial Number
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/22/2014 - 10 years ago
  • Project End Date
    6/21/2015 - 9 years ago
  • Program Officer Name
  • Budget Start Date
    -
  • Budget End Date
    -
  • Fiscal Year
    2014
  • Support Year
  • Suffix
  • Award Notice Date
    -
Organizations

IGF::OT::IGF SBIR PHASE I, TOPIC 331: OPTICAL SPECTROSCOPY CAPABLE BIOPSY NEEDLE TIP TO SEEK HIGH TUMOR CONTENT AREAS

Biopsies are fundamental to the diagnosis, management and treatment of most cancers. A tissue sample enables a pathologist to make a diagnosis of cancer, to determine its type and nuclear grade, and to evaluate for cancer specific biomarkers that affect the plan of action for treatment. To obtain this information, the pathologist needs an adequate specimen of tissue from the lesion in question. Imaging guidance (ultrasound, x-ray or MRI) is used to identify and help sample the lesion. Despite imaging guidance, up to 12% of image-guided needle biopsies are non-diagnostic. Non-diagnostic biopsies result from not sampling the lesion or sampling non-viable portions of the lesion. This project will supplement current biopsy techniques by providing real-time non-destructive optical sampling at the tip of the biopsy needle to enable the operator to locate and sample from the most cellular and most suspicious areas of a lesion. Specifically, this system detects areas of high cellularity (i.e. higher DNA content in a specific volume), increased blood content, and decreased oxygen saturation, which are all associated with malignant cells. This is accomplished by placing a fiber optic based device inside a standard stylet needle, which is routinely used during biopsies. This approach takes advantage of the intrinsic optical contrast between benign and malignant tissue. No intravenous exogenous contrast agent is needed. An easy to understand series of light indicators will provide real-time assessment of the tissue at the tip of the biopsy needle while the operator is guiding the needle toward the lesion of interest. This will direct the operator to place the biopsy needle at the most-suspicious and most cellular parts of the lesion. Using this system, it is expected to decrease the non-diagnostic biopsy rate, allowing earlier and more definitive diagnoses and decreasing anxiety and complications from re-biopsies.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    N43
  • Administering IC
    CA
  • Application Type
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    224977
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:224977\
  • Funding Mechanism
    SBIR/STTR Contracts
  • Study Section
  • Study Section Name
  • Organization Name
    ZIVA CORPORATION
  • Organization Department
  • Organization DUNS
    118614556
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921212758
  • Organization District
    UNITED STATES